#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Asceneuron appoints Eric Yuen to board

Share on Twitter Share on LinkedIn
Christian Fernsby | Lausanne, Switzerland | May 20, 2019
AsceneuronAsceneuron, a healthcare company, announced the appointment of Eric Yuen to its board of directors.
Dr Yuen has over 25 years of clinical development experience in central nervous system (CNS) pathologies and has led multiple Phase I-IV development programs for biologics and small molecules obtaining numerous regulatory approvals.

He is currently Chief Medical Officer at Talee Bio Inc which he co-founded in addition to RiboNova Inc.

Dr Yuen's industry experience began at Merck Sharp and Dohme (known as Merck and Co in the United States) as Director of Clinical Research, where he focused on CNS and pain indications.

He then spent nine years at Johnson and Johnson finally as Vice President of Clinical Development responsible for the portfolio of monoclonal antibodies and vaccines targeting Alzheimer's disease.

He has since held senior positions in several biotech companies including as Chief Medical Officer at Inozyme Pharma and Ultragenyx Pharmaceuticals.

Before joining the industry, Dr Yuen was an assistant professor of neurology at the University of Washington, where he conducted clinical research in rare CNS disorders.

Dr Yuen received his M.D. from the Pritzker School of Medicine at the University of Chicago and completed his neurology training at the University of California at San Francisco.

He holds a B.S. in Physics and Biology with Academic Distinction from Stanford University.